CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update

References

• Ott J, Stevens G, Groeger J, et al. Global epidemiology of hepatitis B infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30, 2212–2219 (2012). 12
   PubMed Web of Science ®Google Scholar
• Kane A, Lloyd J, Zaffran M, et al. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Heal. Organ 77, 801–807 (1999).
   PubMed Web of Science ®Google Scholar
• Schalm S, Osterhaus A. Characteristics of the early phase of chronicity in acute hepatitis B infection. J Med Virol 57, 331–336 (1999). 4
   PubMed Web of Science ®Google Scholar
• Bianco E, Stroffolini T, Spada E, et al. Case fatality rate of acute viral hepatitis in Italy: 1995–2000. An update. Dig Liver Dis 35, 404–408 (2003). 6
   PubMedGoogle Scholar
• ShouvalD. Hepatitis B vaccines. J Hepatol. 39, S70–76 (2003).
   PubMed Web of Science ®Google Scholar
• Chang M. Hepatocellular carcinoma in children. Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih 39, 366–370 (1998). 6
   Google Scholar
• Clements C, Baoping Y, Crouch A, et al. Progress in the control of hepatitis B infection in the western Pacific region. Vaccine 24, 1975–1982 (2006)
   Google Scholar
• Sjogren M. Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination. Am J Med 118, 34S–39S (2005). 10
   PubMed Web of Science ®Google Scholar
• Trevisan A, Borella-Venturini M, Di Marco L Compliance with hepatitis B virus vaccine: a matter of force? Am J Infect Control 34, 465–466 (2006). 7
   PubMed Web of Science ®Google Scholar
• Macdonald V, Dore G, Amin J, et al. Predictors of completion of a hepatitis B vaccination schedule in attendees at a primary health care centre. Sex Heal. 4, 27–30 (2007). 1
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Yamamoto T, Shimada S, et al. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol. 36, 983–997 (1992)
   Google Scholar
• Sonehara K, Saito H, Kuramoto E, et al. Hexamer palindromic oligonucleotides with 5ʹ-CG-3ʹ motif(s) induce production of interferon. J Interf Cytokine Res. (1996). 16 10 799–803
   PubMed Web of Science ®Google Scholar
• Halpern MD, Kurlander RJ, Pisetsky DS Bacterial DNA induces murine interferon-γ production by stimulation of interleukin-12 and tumor necrosis factor-α. Cell Immunol. (1996). 167 1 72–78
   PubMed Web of Science ®Google Scholar
• Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995). 374 6522 546–549
   PubMed Web of Science ®Google Scholar
• Martin-Orozco E, Kobayashi H, Van Uden J, et al. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int Immunol. (1999). 11 7 1111–1118
   Google Scholar
• Sato Y, Roman M, Tighe H, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science (80). (1996). 273 352–354
   PubMed Web of Science ®Google Scholar
• Davis HL, Weeratna R, Waldschmidt TJ, et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol. (1998);160(2):870–6
   PubMed Web of Science ®Google Scholar
• Barry M, Cooper C, Barry M, et al. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. 2598, (2007).
   Google Scholar
• Halperin SA, Van Nest G, Smith B, et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21, 2461–2467 (2003). 19–2z
   Google Scholar
• Lim SG Heplisav™: a new hepatitis B vaccine. Futur. Med. 3, 109–117 (2008).
   Google Scholar
• Halperin SA, Dobson S, McNeil S, et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 24, 20–26 (2006)
   Google Scholar
• Lim SG, Chow WC Recombinant hepatitis B virus surface antigen (rHBsAg) co- administered with an immunostimulatory phosphorothioate oligonucleotide (1018 ISS) provides superior protection in 40-70 year old subjects. In Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, USA. (2005).
   Google Scholar
• Halperin SA, Ward B, Cooper C, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adul. Vaccine 30, 2556–2563 (2012)
   Google Scholar
• Heyward WL, Kyle M, Blumenau J, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40– 70 years of age ଝ. Vaccine 31, 5300–5305 (2013)
   Google Scholar
• Jackson S, Lentino J, Kopp J, et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine 36, 668–674 (2018)
   Google Scholar
• Hyer RN, Janssen RS Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60– 70 years. Vaccine 37, 5854–5861 (2019). 39
   PubMed Web of Science ®Google Scholar
• Janssen RS, Mangoo-karim R, Pergola PE, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine 31, 5306–5313 (2013)
   Google Scholar
• Amjad W, Alukal J, Zhang T, et al. Two-Dose Hepatitis B Vaccine (Heplisav-B) results in better Seroconversion than Three-Dose Vaccine (Engerix-B) in Chronic Liver Disease. Digestive Dis Sci. (2020). doi: 10.1007/s10620-020-06437-6
   Web of Science ®Google Scholar
• Kimball BM, Garrett KL. Novel, two-dose hepatitis B vaccine confers robust immune response in HIV and HCV patients. In Conference on Retroviruses and Opportunistic Infections 0605 (2020).
   Google Scholar
• Walayat S, Ahmed Z, Martin D, et al. Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. World J Hepatol. 7, 2503–2509 (2015)
   Google Scholar
• Jiang H, Wang S, Deng M. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine 35, 2633–2641 (2017). 20
   PubMed Web of Science ®Google Scholar
• Van Den Berg R, Van Hoogstraten I, Van Agtmael M. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev. 2009;11(3):157–164.(2009).
   PubMed Web of Science ®Google Scholar
• Mattos A, Gomes E, Tovo C, et al. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. Arq Gastroenterol 41, 180–184 (2004). 3
   PubMedGoogle Scholar
• Walkiewicz-Jedrzejczak D, Egberg M, Nelson C, et al. Evaluation of the response to vaccination with hepatitis B vaccine in pediatric patients diagnosed with celiac disease. SAGE Open Med 2, 2050312114563346 (2014).
   Google Scholar
• DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 42, 1184–1192 (2003)
   Google Scholar
• Agarwal S, Irshad M, Dash S Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and severe renal failure. J Assoc Physicians India 47, 183–185 (1999). 2
   PubMedGoogle Scholar
• Hyer R, Mcguire DK, Xing B, et al. Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults. Vaccine 36, 2604–2611 (2018). 19
   PubMed Web of Science ®Google Scholar
• Schillie S, Harris A, Link-gelles R, et al. Recommendations of the advisory committee on immunization practices for use of a Hepatitis B Vaccine with a novel adjuvant. 67, 455–458 (2018).MMWR. Morbidity and mortality weekly report 15
   Google Scholar
• Kuan RK, Janssen R, Heyward W, et al. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine. Vaccine 31, 4024–4032 (2013). 37
   PubMed Web of Science ®Google Scholar
• Rosenthal EM, Hall EW, Rosenberg ES, et al. Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations. Vaccine 38, 8206–8215 (2020)
   Google Scholar
• Shapira M, Zeira E, Adler R, et al. Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. J Hepatol. 34, 123–127 (2001). 1
   PubMed Web of Science ®Google Scholar
• Rendi-Wagner P, Shouval D, Genton B, et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 24, 2781–2789 (2006)
   Google Scholar
• VBI vaccines announces second pivotal phase 3 study of Sci-B-Vac® meets primary and secondary endpoints. Businesswire (2020). Available at: https://www.businesswire.com/news/home/20200109005179/en/VBI-Vaccines-Announces-Pivotal-Phase-3-Study. ( Accessed: 2020 Apr 15th)
   Google Scholar
• Yap I, Chan S. A new pre-S containing recombinant hepatitis B vaccine and its effect on non-responders: a preliminary observation. Ann Acad Med Singapore 25, 120–122 (1996). 1
   PubMedGoogle Scholar
• Heshin-Bekenstein M, Turner D, Shamir R, et al. Hepatitis B virus revaccination with standard versus pre-S vaccine in previously immunized patients with celiac disease. J Pediatr Gastroenterol Nutr. 61, 400–403 (2015)
   Google Scholar
• Alon D, Stein GY, Hadas-Golan V, et al. Immunogenicity of Sci-B-Vac (a third-generation hepatitis B vaccine) in HIV-positive adults. Isr Med Assoc J 19, 143–146 (2017)
   Google Scholar
• Wong TCL, Fung J, Chok K, et al. Hepatitis B vaccination in patients receiving oral antiviral therapy without hepatitis B immunoglobulin after liver transplant. Transplant Proc. 50, 3681–3688 (2018)
   Google Scholar
• Lo CM, Lau GK, Chan SC, et al. Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant. 7, 434–439 (2007). 2
   PubMed Web of Science ®Google Scholar
• Hung IF-N, Yap DY, Yip TP, et al. A double-blind, randomized phase 2 controlled trial of intradermal hepatitis B vaccination with a topical toll-like receptor 7 agonist imiquimod, in patients on dialysis. Clin Infect Dis. 1–8 (2020). doi:10.1093/cid/ciaa804
   Google Scholar
• National Academies of Sciences Engineering and Medicine. A national strategy for the elimination of hepatitis B and C: phase Two report. Washington, DC Natl. Acad. Press (2017). doi: 10.17226/24731
   Google Scholar
• Williams WW, Lu PJ, O'Halloran A, et al. Surveillance of vaccination coverage among adult populations—United States, 2015. MMWR Surveill. Summ. (2017). 66 11 1–28
   Google Scholar
• Kilmer G, Barker L, Ly K, et al. Hepatitis B vaccination and screening among foreign-born women of reproductive age in the United States: 2013-2015. Clin Infect Dis 68, 256–265 (2019). 2
   PubMed Web of Science ®Google Scholar